Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer-Reference-Cited by-同舟云学术

Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer

Published:2016-02-12 Issue:1 Volume:8 Page:
ISSN:1868-7075
Container-title:Clinical Epigenetics
language:en
Short-container-title:Clin Epigenet

Author:

Clermont Pier-Luc,Crea Francesco,Chiang Yan Ting,Lin Dong,Zhang Amy,Wang James Z. L.,Parolia Abhijit,Wu Rebecca,Xue Hui,Wang Yuwei,Ding Jiarui,Thu Kelsie L.,Lam Wan L.,Shah Sohrab P.,Collins Colin C.,Wang Yuzhuo,Helgason Cheryl D.

Funder

Canadian Cancer Society Research Institute

Canadian Institutes of Health Research (CA)

Terry Fox Research Institute

Prostate Cancer Canada

BC Cancer Foundation

Michael Smith Foundation for Health Research

Publisher

Springer Science and Business Media LLC

Subject

Genetics(clinical),Developmental Biology,Genetics,Molecular Biology

Link

http://link.springer.com/content/pdf/10.1186/s13148-016-0182-9

Reference41 articles.

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.

2. Horwich A, Hugosson J, de Reijke T, et al. Prostate cancer: ESMO consensus conference guidelines 2012. Ann Oncol. 2013;24:1141–62.

3. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34–45.

4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

5. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of substituted acetanilide compounds as small molecule CBX2 inhibitors via in silico screening;2024-09-11

2. Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer;European Journal of Medical Research;2024-08-22

3. CBX2 enhances the progression and TMZ chemoresistance of glioma via EZH2-mediated epigenetic silencing of PTEN expression;Frontiers in Pharmacology;2024-07-24

4. Comprehensive molecular analyses and experimental validation of CDCAs with potential implications in kidney renal papillary cell carcinoma prognosis;Heliyon;2024-06

5. PRADclass: Hybrid Gleason Grade-Informed Computational Strategy Identifies Consensus Biomarker Features Predictive of Aggressive Prostate Adenocarcinoma;Technology in Cancer Research & Treatment;2024-01